問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林昱廷

Recruiting

List

7Cases

2024-11-12 - 2030-12-19

Phase III

Active
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjogren’s Disease (SjD)

  • Condition/Disease

    Moderate to Severe Sjogren’s Disease (SjD)

  • Test Drug

    injective

Participate Sites
7Sites

Recruiting7Sites

2024-12-20 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-01-03 - 2029-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-07-01 - 2027-01-31

Phase II

Active
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome

  • Condition/Disease

    Sjögren’s Syndrome

  • Test Drug

    injection

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2022-12-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-08-01 - 2027-05-31

Phase III

Active
A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants with Gout

  • Condition/Disease

    Gout

  • Test Drug

    AR882

Participate Sites
7Sites

Recruiting7Sites

2024-09-01 - 2030-10-28

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB